XML 57 R36.htm IDEA: XBRL DOCUMENT v3.7.0.1
Business and Basis of Presentation (Additional Information) (Detail) - USD ($)
 1 Months Ended 2 Months Ended 6 Months Ended 12 Months Ended
Feb. 13, 2017
Jul. 13, 2016
Jan. 12, 2016
Apr. 10, 2015
Mar. 18, 2015
Nov. 18, 2014
Apr. 10, 2015
Feb. 28, 2017
Jun. 30, 2017
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2014
Aug. 07, 2017
Mar. 15, 2017
Feb. 06, 2017
Jul. 29, 2016
Jun. 30, 2016
May 10, 2016
Dec. 31, 2013
May 08, 2013
Schedule Of Summary Of Significant Accounting Policies [Line Items]                                        
Cash and cash equivalents                 $ 18,073,000 $ 18,083,000 $ 29,730,000 $ 23,650,000         $ 19,590,000   $ 47,787,000  
Issuance of common stock, shares     988,636         3,541,077                        
Price per unit     $ 22.00                                  
Exercise price (usd per share)   $ 13.00 $ 28.40           $ 79.40 $ 79.40 $ 79.40         $ 8.60   $ 30.20   $ 49.4
Proceeds from issuance of shares, net underwriting discounts, commissions and offering expenses     $ 20,200,000                                  
debenture outstanding                 $ 19,100,000                     $ 10,000,000
Highly-liquid debt instruments maturity days                   90 days                    
Income tax expense                   $ 243,000 $ 365,000 $ 0                
Interest bearing accounts                   $ 17,583,000                    
Number of shares availabe from warrants                                       9,109
Debt instrument, covenant, compensating cash balance                 13,200,000                      
Senior Secured Debentures                                        
Schedule Of Summary Of Significant Accounting Policies [Line Items]                                        
Principle amount of debt                 $ 25,500,000                      
Funding NeuVax in 2019 | Subsequent Event                                        
Schedule Of Summary Of Significant Accounting Policies [Line Items]                                        
Funding commitment in 2019                         $ 3,000,000              
Common Stock                                        
Schedule Of Summary Of Significant Accounting Policies [Line Items]                                        
Issuance of common stock, shares   1,400,000               2,872,803 1,607,934 331,650                
Price per unit   $ 9.00                                    
Issuance of common stock upon redemption                 5,150,660 20,403   273,351                
Out-Of-The-Money Warrants | Subsequent Event                                        
Schedule Of Summary Of Significant Accounting Policies [Line Items]                                        
Number of shares availabe from warrants                         2,556,851              
Underwritten Public Offering                                        
Schedule Of Summary Of Significant Accounting Policies [Line Items]                                        
Issuance of common stock, shares         1,217,948                              
Exercise price (usd per share)         $ 41.60                              
Proceeds from issuance of shares, net underwriting discounts, commissions and offering expenses       $ 5,400,000     $ 40,800,000                          
Number of shares availabe from warrants         0.50                              
Underwritten Public Offering | Common Stock                                        
Schedule Of Summary Of Significant Accounting Policies [Line Items]                                        
Issuance of common stock, shares 17,000,000                                      
Price per unit $ 1.00   $ 1.00                                  
Proceeds from underwritten public offering $ 17,000,000                                      
Exercise price (usd per share) $ 1.10                                      
Proceeds from issuance of shares, net underwriting discounts, commissions and offering expenses $ 15,500,000                                      
Redepmtion of debt through issuance of common stock               $ 3,950,000                        
Issuance of common stock upon redemption               3,518,663                        
Decrease in restricted cash and cash equivalent               $ 3,950,000                        
debenture outstanding                           $ 13,617,702            
Lincoln Park Capital, LLC Purchase Agreement                                        
Schedule Of Summary Of Significant Accounting Policies [Line Items]                                        
Issuance of common stock, shares                   150,000 135,000 230,000                
Remaining authorized repurchase amount                 $ 2,000,000           $ 2,100,000          
Lincoln Park Capital, LLC Purchase Agreement | Common Stock                                        
Schedule Of Summary Of Significant Accounting Policies [Line Items]                                        
Issuance of common stock, shares           31,561                            
Galena Biopharma, Inc | Subsequent Event                                        
Schedule Of Summary Of Significant Accounting Policies [Line Items]                                        
Ownership percentage by Parent                         32.50%              
Galena Biopharma, Inc | SELLAS | Subsequent Event                                        
Schedule Of Summary Of Significant Accounting Policies [Line Items]                                        
Percentage of voting interests acquired                         67.50%              
Minimum | Equipment and Furnishings [Member]                                        
Schedule Of Summary Of Significant Accounting Policies [Line Items]                                        
Estimated useful lives                   3 years                    
Maximum | Equipment and Furnishings [Member]                                        
Schedule Of Summary Of Significant Accounting Policies [Line Items]                                        
Estimated useful lives                   5 years